KOCH KEVIN 4
4 · Edgewise Therapeutics, Inc. · Filed Mar 11, 2025
Insider Transaction Report
Form 4
KOCH KEVIN
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-03-07$30.00/sh−100$3,000→ 14,478 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-03-07−100→ 41,545 totalExercise: $0.18From: 2021-06-13Exp: 2027-08-08→ Common Stock (100 underlying) - Exercise/Conversion
Common Stock
2025-03-07$0.18/sh+100$18→ 14,578 total
Holdings
- 26,410(indirect: By Trust)
Common Stock
- 259,554(indirect: By LLC)
Common Stock
- 26,410(indirect: By Trust)
Common Stock
- 26,410(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024.
- [F2]These shares are held directly by the KTK Family Enterprise, LLC for the which the Reporting Person serves as Manager.
- [F3]These shares are held directly by the Nicole M. Soldow Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
- [F4]These shares are held directly by the Adrienne R. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
- [F5]These shares are held directly by the Matthew K. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.